出院时处方四联药物治疗的射血分数降低型心衰住院患者的一年结局
本研究基于美国医保人群回顾性队列,纳入2021年7月至2023年12月因HFrEF住院并在出院时接受四联药物治疗的患者1490例,评估一年临床结局与医疗费用。
要点
- 出院时接受四联药物治疗的HFrEF患者一年死亡率为19.3%。
- 一年心衰再住院率26.0%,死亡或再住院复合终点37.1%。
- 四联药物处方率仅7.2%,医院间差异显著。
核心结论
- 即使出院时处方了四联药物治疗,老年HFrEF住院患者仍面临较高的死亡和心衰再住院残余风险,且医疗费用负担重。
研究设计与样本
- 回顾性队列研究,纳入美国医保受益人中因HFrEF住院且出院时接受四联药物治疗的患者。
主要发现
- 一年全因死亡累计发生率19.3%(95%CI 17.3%-21.4%)。
- 一年心衰再住院累计发生率26.0%(95%CI 23.6%-28.5%)。
- 一年全因死亡或心衰再住院复合终点发生率37.1%(95%CI 34.4%-39.8%)。
关键数值与推荐
- 四联药物治疗定义为出院时同时处方血管紧张素受体-脑啡肽酶抑制剂、β受体阻滞剂、盐皮质激素受体拮抗剂和钠-葡萄糖协同转运蛋白2抑制剂。
- 主要结局为死亡率、心衰住院、死亡或心衰住院复合终点,以及每位患者的医疗支出(Medicare A和B部分住院与门诊费用,以2023年美元计)。
临床怎么用
- 提示即使在临床实践中处方了指南推荐的四联疗法,仍需关注患者的残余风险,加强出院后随访与管理。
- 医院间四联药物处方率差异大(中位OR 2.04),提示需优化治疗落实的标准化流程。
局限性
- 观察性研究,存在残余混杂可能。
- 仅纳入Medicare受益人群,结果外推至年轻或其他保险人群需谨慎。
- 处方不等于实际服药,依从性未评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Among patients with heart failure with reduced ejection fraction (HFrEF) in US clinical practice, the residual risk of poor clinical outcomes despite quadruple medical therapy is not well characterized. OBJECTIVE: To evaluate clinical outcomes and health care costs among patients hospitalized for HFrEF prescribed quadruple medical therapy at discharge. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study examined Medicare beneficiaries hospitalized for HFrEF in the Get With The Guidelines-Heart Failure registry and discharged from US hospitals receiving any dose of quadruple medical therapy (angiotensin receptor-neprilysin inhibitor, β-blocker, mineralocorticoid receptor antagonist, and sodium-glucose cotransporter 2 inhibitor) between July 1, 2021, and December 31, 2023. Data analysis was conducted from October 2024 through March 2025. EXPOSURE: Prescription of quadruple medical therapy (angiotensin receptor-neprilysin inhibitor, β-blocker, mineralocorticoid receptor antagonist, and sodium-glucose cotransporter 2 inhibitor) at time of hospital discharge. MAIN OUTCOMES AND MEASURES: The primary outcomes were mortality, HF hospitalization, mortality or HF hospitalization, and per-patient health care expenditure (Medicare Part A and B inpatient and outpatient costs, in 2023 US dollars). RESULTS: Among 20 651 patients with HFrEF eligible for quadruple medical therapy across 532 US hospitals, 1490 (7.2%) were prescribed quadruple therapy at discharge, with high between-hospital variance (median odds ratio, 2.04; 95% CI, 1.89-2.24). Median (IQR) age of patients prescribed quadruple therapy was 74 (69-81) years, and 543 patients (36.4%) were women. Over 12-month follow-up, cumulative incidences of all-cause mortality, HF hospitalization, and all-cause mortality or HF hospitalization were 19.3% (95% CI, 17.3%-21.4%), 26.0% (95% CI, 23.6%-28.5%), and 37.1% (95% CI, 34.4%-39.8%), respectively. Median (IQR) 12-month per-patient health care expenditure was $27 956 ($7478-$61 126). Twelve-month mortality and HF hospitalization outcomes were similar for patients prescribed quadruple medical therapy at discharge in the first half vs the second half of the study period. CONCLUSIONS AND RELEVANCE: In this nationwide cohort study, even when prescribed quadruple medical therapy, older patients hospitalized for HFrEF in US clinical practice face substantial residual risk of death and HF readmission and often accrue high health care costs.
引用
- Greene, Xu, Chiswell, et al. One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge. JAMA Cardiol. 2026. PMID: 41604197. doi:10.1001/jamacardio.2025.5339
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。